{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:30:28Z","timestamp":1771479028797,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,17]]},"DOI":"10.7759\/cureus.19658","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T12:32:55Z","timestamp":1637152375000},"source":"Crossref","is-referenced-by-count":6,"title":["Pediatric Chemotherapy Drugs Associated With Cardiotoxicity"],"prefix":"10.7759","author":[{"given":"Gazala","family":"Hitawala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisett","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Akku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adila K","family":"Chamavaliyathil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikash","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Quinonez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Dakroub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H","family":"Baloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan S","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dylewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30186-9","article-title":"International incidence of childhood cancer, 2001-10: a population-based registry study","volume":"18","author":"Steliarova-Foucher E","year":"2017","unstructured":"Steliarova-Foucher E, Colombet M, Ries LA, et al.. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017, 18:719-31. 10.1016\/S1470-2045(17)30186-9","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30909-4","article-title":"Estimating the total incidence of global childhood cancer: a simulation-based analysis","volume":"20","author":"Ward ZJ","year":"2019","unstructured":"Ward ZJ, Yeh JM, Bhakta N, et al.. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol.. 2019, 20:483-93. 10.1016\/S1470-2045(18)30909-4","journal-title":"Lancet Oncol."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.02.006","article-title":"Pediatric cancer models in Zebrafish","volume":"6","author":"Casey MJ","year":"2020","unstructured":"Casey MJ, Stewart RA. Pediatric cancer models in Zebrafish. Trends Cancer. 2020, 6:407-18. 10.1016\/j.trecan.2020.02.006","journal-title":"Trends Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1351547","article-title":"Chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Bansal N","year":"2017","unstructured":"Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol. 2017, 13:817-32. 10.1080\/17425255.2017.1351547","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz031","article-title":"Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment","volume":"115","author":"Chow EJ","year":"2019","unstructured":"Chow EJ, Leger KJ, Bhatt NS, et al.. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovasc Res. 2019, 115:922-34. 10.1093\/cvr\/cvz031","journal-title":"Cardiovasc Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review","volume":"40","author":"Liesse K","year":"2018","unstructured":"Liesse K, Harris J, Chan M, Schmidt ML, Chiu B. Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review. J Pediatr Hematol Oncol. 2018, 40:417-25. 10.1097\/MPH.0000000000001118","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100015","article-title":"Predicting and preventing anthracycline-related cardiotoxicity","volume":"38","author":"Armenian S","year":"2018","unstructured":"Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018, 38:3-12. 10.1200\/EDBK_100015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101394","article-title":"Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?","volume":"29","author":"Kalyanaraman B","year":"2020","unstructured":"Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?. Redox Biol. 2020, 29:101394. 10.1016\/j.redox.2019.101394","journal-title":"Redox Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia","volume":"18","author":"El-Shitany NA","year":"2012","unstructured":"El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012, 18:607-13. 10.1016\/j.cardfail.2012.06.416","journal-title":"J Card Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt P","year":"2018","unstructured":"Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018, 14:2663-76. 10.2217\/fon-2018-0210","journal-title":"Future Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1311","article-title":"Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling","volume":"105","author":"Tripaydonis A","year":"2019","unstructured":"Tripaydonis A, Conyers R, Elliott DA. Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling. Clin Pharmacol Ther. 2019, 105:614-24. 10.1002\/cpt.1311","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-017-0826-1","article-title":"Mechanisms of cardiomyocyte proliferation and differentiation in development and regeneration","volume":"19","author":"Yester JW","year":"2017","unstructured":"Yester JW, K\u00fchn B. Mechanisms of cardiomyocyte proliferation and differentiation in development and regeneration. Curr Cardiol Rep. 2017, 19:13. 10.1007\/s11886-017-0826-1","journal-title":"Curr Cardiol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191169098","article-title":"Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival","volume":"98","author":"Oh H","year":"2001","unstructured":"Oh H, Taffet GE, Youker KA, Entman ML, Overbeek PA, Michael LH, Schneider MD. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc Natl Acad Sci U S A. 2001, 98:10308-13. 10.1073\/pnas.191169098","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.184549","article-title":"Knockdown of cyclin-dependent kinase inhibitors induces cardiomyocyte re-entry in the cell cycle","volume":"286","author":"Di Stefano V","year":"2011","unstructured":"Di Stefano V, Giacca M, Capogrossi MC, Crescenzi M, Martelli F. Knockdown of cyclin-dependent kinase inhibitors induces cardiomyocyte re-entry in the cell cycle. J Biol Chem. 2011, 286:8644-54. 10.1074\/jbc.M110.184549","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science\/6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey KM","year":"1984","unstructured":"Tewey KM, Rowe TC, Yang L, et al.. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984, 226:466-8. 10.1126\/science\/6093249","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang S","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012, 18:1639-42. 10.1038\/nm.2919","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet A","year":"2016","unstructured":"Maillet A, Tan K, Chai X, et al.. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci Rep. 2016, 6:25333. 10.1038\/srep25333","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3374","article-title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng F","year":"2015","unstructured":"Aminkeng F, Bhavsar AP, Visscher H, et al.. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015, 47:1079-84. 10.1038\/ng.3374","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.093849","article-title":"Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A","volume":"86","author":"Hanna AD","year":"2014","unstructured":"Hanna AD, Lam A, Tham S, Dulhunty AF, Beard NA. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Mol Pharmacol. 2014, 86:438-49. 10.1124\/mol.114.093849","journal-title":"Mol Pharmacol"},{"key":"ref20","article-title":"Human carbonyl reductase overexpression in the heart advances the development of doxorubicn-induced cardiotoxicity in transfenic mice","volume":"60","author":"Forrest GL","year":"2020","unstructured":"Forrest GL, Gonzalez B, Tseng W, et al.. Human carbonyl reductase overexpression in the heart advances the development of doxorubicn-induced cardiotoxicity in transfenic mice. Cancer Res. 2020, 60:5158-64.","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group","volume":"30","author":"Blanco JG","year":"2012","unstructured":"Blanco JG, Sun CL, Landier W, et al.. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol. 2012, 30:1415-21. 10.1200\/JCO.2011.34.8987","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco JG","year":"2008","unstructured":"Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al.. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008, 112:2789-95. 10.1002\/cncr.23534","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.052209","article-title":"Mrp1 localization and function in cardiac mitochondria after doxorubicin","volume":"75","author":"Jungsuwadee P","year":"2009","unstructured":"Jungsuwadee P, Nithipongvanitch R, Chen Y, Oberley TD, Butterfield DA, St Clair DK, Vore M. Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol Pharmacol. 2009, 75:1117-26. 10.1124\/mol.108.052209","journal-title":"Mol Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.2.7","article-title":"The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart","volume":"58","author":"Couture L","year":"2006","unstructured":"Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev. 2006, 58:244-58. 10.1124\/pr.58.2.7","journal-title":"Pharmacol Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1042\/CBI20110264","article-title":"ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia","volume":"36","author":"Semsei AF","year":"2012","unstructured":"Semsei AF, Erdelyi DJ, Ungvari I, et al.. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int. 2012, 36:79-86. 10.1042\/CBI20110264","journal-title":"Cell Biol Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian SH","year":"2013","unstructured":"Armenian SH, Ding Y, Mills G, et al.. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol. 2013, 163:205-13. 10.1111\/bjh.12516","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia","volume":"16","author":"Krajinovic M","year":"2016","unstructured":"Krajinovic M, Elbared J, Drouin S, et al.. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016, 16:530-5. 10.1038\/tpj.2015.63","journal-title":"Pharmacogenomics J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher H","year":"2012","unstructured":"Visscher H, Ross CJ, Rassekh SR, et al.. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012, 30:1422-8. 10.1200\/JCO.2010.34.3467","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher H","year":"2013","unstructured":"Visscher H, Ross CJ, Rassekh SR, et al.. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013, 60:1375-81. 10.1002\/pbc.24505","journal-title":"Pediatr Blood Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.03.032","article-title":"The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response","volume":"157","author":"Puente BN","year":"2014","unstructured":"Puente BN, Kimura W, Muralidhar SA, et al.. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. Cell. 2014, 157:565-79. 10.1016\/j.cell.2014.03.032","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)88854-8","article-title":"Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen","volume":"260","author":"Gianni L","year":"1985","unstructured":"Gianni L, Zweier JL, Levy A, et al.. Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J Biol Chem. 1985, 260:6820-6.","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.12.9337145","article-title":"Adriamycin cardiomyopathy: pathophysiology and prevention","volume":"11","author":"Singal PK","year":"1997","unstructured":"Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997, 11:931-6. 10.1096\/fasebj.11.12.9337145","journal-title":"FASEB J"},{"key":"ref33","article-title":"Anthracycline cardiomyopathy monitored by morphologic changes","volume":"62","author":"Billingham ME","year":"1978","unstructured":"Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978, 62:865-72.","journal-title":"Cancer Treat Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2017.06.009","article-title":"Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity","volume":"30","author":"Glass CK","year":"2017","unstructured":"Glass CK, Mitchell RN. Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. Cardiovasc Pathol. 2017, 30:55-63. 10.1016\/j.carpath.2017.06.009","journal-title":"Cardiovasc Pathol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2664","article-title":"Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy","volume":"70","author":"Zhao Y","year":"2010","unstructured":"Zhao Y, McLaughlin D, Robinson E, et al.. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res. 2010, 70:9287-97. 10.1158\/0008-5472.CAN-10-2664","journal-title":"Cancer Res"},{"key":"ref36","article-title":"Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents","volume":"59","author":"Garner AP","year":"1999","unstructured":"Garner AP, Paine MJI, Rodriguez-Crespo I, et al.. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Research. 1999, 59:1929-34.","journal-title":"Cancer Research"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903177212","article-title":"Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood","volume":"50","author":"Raji\u0107 V","year":"2009","unstructured":"Raji\u0107 V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009, 50:1693-8. 10.1080\/10428190903177212","journal-title":"Leuk Lymphoma"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26472","article-title":"Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study","volume":"118","author":"Windsor RE","year":"2012","unstructured":"Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012, 118:1856-67. 10.1002\/cncr.26472","journal-title":"Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.01.076","article-title":"Identification of genes related to heart failure using global gene expression profiling of human failing myocardium","volume":"393","author":"Min KD","year":"2010","unstructured":"Min KD, Asakura M, Liao Y, et al.. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun. 2010, 393:55-60. 10.1016\/j.bbrc.2010.01.076","journal-title":"Biochem Biophys Res Commun"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvt226","article-title":"Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling","volume":"101","author":"Ronkainen VP","year":"2014","unstructured":"Ronkainen VP, Tuomainen T, Huusko J, et al.. Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. Cardiovasc Res. 2014, 101:69-77. 10.1093\/cvr\/cvt226","journal-title":"Cardiovasc Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3557","article-title":"Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group","volume":"32","author":"Wang X","year":"2014","unstructured":"Wang X, Liu W, Sun CL, et al.. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol. 2014, 32:647-53. 10.1200\/JCO.2013.50.3557","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2012.11.006","article-title":"Hyaluronic acid-dependent protection in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment","volume":"303","author":"Law CH","year":"2013","unstructured":"Law CH, Li JM, Chou HC, Chen YH, Chan HL. Hyaluronic acid-dependent protection in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment. Toxicology. 2013, 303:54-71. 10.1016\/j.tox.2012.11.006","journal-title":"Toxicology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09517-2","article-title":"Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term cildhood cancer survivors","volume":"7","author":"Hildebrandt MA","year":"2017","unstructured":"Hildebrandt MA, Reyes M, Wu X, et al.. Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term cildhood cancer survivors. Sci Rep. 2017, 7:9698. 10.1038\/s41598-017-09517-2","journal-title":"Sci Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0869","article-title":"Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin","volume":"102","author":"Miranda CJ","year":"2003","unstructured":"Miranda CJ, Makui H, Soares RJ, et al.. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood. 2003, 102:2574-80. 10.1182\/blood-2003-03-0869","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"119","author":"Lipshultz SE","year":"2013","unstructured":"Lipshultz SE, Lipsitz SR, Kutok JL, et al.. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013, 119:3555-62. 10.1002\/cncr.28256","journal-title":"Cancer"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4550","article-title":"CELF4 variant and anthracycline-related cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study","volume":"34","author":"Wang X","year":"2016","unstructured":"Wang X, Sun CL, Qui\u00f1ones-Lombra\u00f1a A, et al.. CELF4 variant and anthracycline-related cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. J Clin Oncol. 2016, 34:863-70. 10.1200\/JCO.2015.63.4550","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(17)39158-5","article-title":"A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing","volume":"260","author":"Cooper TA","year":"1985","unstructured":"Cooper TA, Ordahl CP. A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing. J Biol Chem. 1985, 260:11140-8.","journal-title":"J Biol Chem"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200106000-00008","article-title":"Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study","volume":"23","author":"Hurwitz CA","year":"2001","unstructured":"Hurwitz CA, Strauss LC, Kepner J, et al.. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol. 2001, 23:277-81. 10.1097\/00043426-200106000-00008","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom H","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, et al.. Cremophor EL the drawbacks and advantages of vehicle selection for drug formulation . Eur J Cancer. 2001, 37:1590-8. 10.1016\/S0959-8049(01)00171-X","journal-title":"Eur J Cancer"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90298-3","article-title":"Histamine and the human heart: the other receptor system","volume":"49","author":"Bristow MR","year":"1982","unstructured":"Bristow MR, Ginsburg R, Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol. 1982, 49:249-51. 10.1016\/0002-9149(82)90298-3","journal-title":"Am J Cardiol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac disturbances during the administration of taxol","volume":"9","author":"Rowinsky EK","year":"1991","unstructured":"Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991, 9:1704-12. 10.1200\/JCO.1991.9.9.1704","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1080\/07357900701513074","article-title":"Tyrosine kinase inhibitors in pediatric malignancies","volume":"25","author":"Skolnik JM","year":"2007","unstructured":"Skolnik JM, Adamson PC. Tyrosine kinase inhibitors in pediatric malignancies. Cancer Invest. 2007, 25:606-12. 10.1080\/07357900701513074","journal-title":"Cancer Invest"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4 R","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R, et al.. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006, 12:908-16. 10.1038\/nm1446","journal-title":"Nat Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(00)80008-1","article-title":"Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor","volume":"35","author":"Rowe DH","year":"2000","unstructured":"Rowe DH, Huang J, Kayton M, et al.. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 2000, 35:30-3. 10.1016\/S0022-3468(00)80008-1","journal-title":"J Pediatr Surg"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2000.6946","article-title":"Suppression of primary tumor growth in a mouse model of human neuroblastoma","volume":"35","author":"Rowe DH","year":"2000","unstructured":"Rowe DH, Huang J, Li J, et al.. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg. 2000, 35:977-81. 10.1053\/jpsu.2000.6946","journal-title":"J Pediatr Surg"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2003.50099","article-title":"Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis","volume":"38","author":"McCrudden KW","year":"2003","unstructured":"McCrudden KW, Hopkins B, Frischer J, et al.. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003, 38:308-14. 10.1053\/jpsu.2003.50099","journal-title":"J Pediatr Surg"},{"key":"ref57","article-title":"Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor","volume":"60","author":"Gerber HP","year":"2000","unstructured":"Gerber HP, Kowalski J, Sherman D, et al.. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000, 60:6253-8.","journal-title":"Cancer Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-303713","article-title":"Cardiac complications and manifestations of chemotherapy for cancer","volume":"100","author":"Khawaja MZ","year":"2014","unstructured":"Khawaja MZ, Cafferkey C, Rajani R, Redwood S, Cunningham D. Cardiac complications and manifestations of chemotherapy for cancer. Heart. 2014, 100:1133-40. 10.1136\/heartjnl-2013-303713","journal-title":"Heart"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000183672.15133.ab","article-title":"Update on angiogenesis inhibitors","volume":"17","author":"Zakarija A","year":"2005","unstructured":"Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol. 2005, 17:578-83. 10.1097\/01.cco.0000183672.15133.ab","journal-title":"Curr Opin Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas C","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, et al.. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008, 134:75-82. 10.1007\/s00432-007-0250-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9226-8","article-title":"5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels","volume":"27","author":"Salepci T","year":"2010","unstructured":"Salepci T, Seker M, Uyarel H, et al.. 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol. 2010, 27:416-20. 10.1007\/s12032-009-9226-8","journal-title":"Med Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6","article-title":"5-Fluorouracil-associated cardiotoxicity","volume":"61","author":"Freeman NJ","year":"1988","unstructured":"Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer. 1988, 61:36-45. 10.1002\/1097-0142(19880101)61:1&lt;36::AID-CNCR2820610108&gt;3.0.CO;2-6","journal-title":"Cancer"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg MA","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, et al.. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986, 68:1114-8. 10.1182\/blood.V68.5.1114.1114","journal-title":"Blood"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1177\/2324709613480346","article-title":"Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management","volume":"1","author":"Dhesi S","year":"2013","unstructured":"Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, Kim DH. Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. J Investig Med High Impact Case Rep. 2013, 1:2324709613480346. 10.1177\/2324709613480346","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200507030-00005","article-title":"Cardiotoxicity of cancer chemotherapy: implications for children","volume":"7","author":"Simbre VC","year":"2005","unstructured":"Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs. 2005, 7:187-202. 10.2165\/00148581-200507030-00005","journal-title":"Paediatr Drugs"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz SE","year":"1991","unstructured":"Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991, 324:808-15. 10.1056\/NEJM199103213241205","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-010-9878-3","article-title":"Anthracycline-associated cardiotoxicity in survivors of childhood cancer","volume":"32","author":"Trachtenberg BH","year":"2011","unstructured":"Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, Lipshultz SE. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011, 32:342-53. 10.1007\/s00246-010-9878-3","journal-title":"Pediatr Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai VB","year":"2000","unstructured":"Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000, 22:263-302. 10.2165\/00002018-200022040-00002","journal-title":"Drug Saf"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/942090","article-title":"Review of cardiotoxicity in pediatric cancer patients: during and after therapy","volume":"2011","author":"Fulbright JM","year":"2011","unstructured":"Fulbright JM. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011, 2011:942090. 10.4061\/2011\/942090","journal-title":"Cardiol Res Pract"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-014-0085-1","article-title":"Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers","volume":"16","author":"Lipshultz SE","year":"2014","unstructured":"Lipshultz SE, Diamond MB, Franco VI, et al.. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. Paediatr Drugs. 2014, 16:373-89. 10.1007\/s40272-014-0085-1","journal-title":"Paediatr Drugs"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3390\/hearts2010005","article-title":"Diagnosis, prevention, treatment and surveillance of anthracycline-induced cardiovascular toxicity in pediatric cancer survivors","volume":"2","author":"Curren V","year":"2021","unstructured":"Curren V, Dham N, Spurney C. Diagnosis, prevention, treatment and surveillance of anthracycline-induced cardiovascular toxicity in pediatric cancer survivors. Hearts. 2021, 2:45-60. 10.3390\/hearts2010005","journal-title":"Hearts"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70042-7","article-title":"Cardiovascular toxicity caused by cancer treatment: strategies for early detection","volume":"10","author":"Altena R","year":"2009","unstructured":"Altena R, Perik PJ, van Veldhuisen PDJ, et al.. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009, 10:391-9. 10.1016\/S1470-2045(09)70042-7","journal-title":"Lancet Oncol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00924","article-title":"Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations","volume":"17","author":"Stone JR","year":"2021","unstructured":"Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021, 17:228-36. 10.1200\/OP.20.00924","journal-title":"JCO Oncol Pract"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2018.05.005","article-title":"Advanced imaging modalities to detect cardiotoxicity","volume":"42","author":"Awadalla M","year":"2018","unstructured":"Awadalla M, Hassan MZ, Alvi RM, Neilan TG. Advanced imaging modalities to detect cardiotoxicity. Curr Probl Cancer. 2018, 42:386-96. 10.1016\/j.currproblcancer.2018.05.005","journal-title":"Curr Probl Cancer"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.008869","article-title":"Echocardiographic assessment of cardiac function in pediatric survivors of anthracycline-treated childhood cancer","volume":"12","author":"Slieker MG","year":"2019","unstructured":"Slieker MG, Fackoury C, Slorach C, et al.. Echocardiographic assessment of cardiac function in pediatric survivors of anthracycline-treated childhood cancer. Circ Cardiovasc Imaging. 2019, 12:e008869. 10.1161\/CIRCIMAGING.119.008869","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac\u00a0dysfunction in adult survivors of\u00a0childhood cancer: Results From the St. Jude Lifetime Cohort Study","volume":"65","author":"Armstrong GT","year":"2015","unstructured":"Armstrong GT, Joshi VM, Ness KK, et al.. Comprehensive echocardiographic detection of treatment-related cardiac\u00a0dysfunction in adult survivors of\u00a0childhood cancer: Results From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015, 65:2511-22. 10.1016\/j.jacc.2015.04.013","journal-title":"J Am Coll Cardiol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana JC","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al.. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014, 27:911-39. 10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.000899","article-title":"Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review","volume":"6","author":"Thavendiranathan P","year":"2013","unstructured":"Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013, 6:1080-91. 10.1161\/CIRCIMAGING.113.000899","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.019","article-title":"Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer","volume":"61","author":"Yl\u00e4nen K","year":"2013","unstructured":"Yl\u00e4nen K, Poutanen T, Savikurki-Heikkil\u00e4 P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013, 61:1539-47. 10.1016\/j.jacc.2013.01.019","journal-title":"J Am Coll Cardiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong GT","year":"2012","unstructured":"Armstrong GT, Plana JC, Zhang N, et al.. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012, 30:2876-84. 10.1200\/JCO.2011.40.3584","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00009","article-title":"Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy","volume":"56","author":"Wiseman LR","year":"1998","unstructured":"Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs. 1998, 56:385-403. 10.2165\/00003495-199856030-00009","journal-title":"Drugs"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake D","year":"2012","unstructured":"Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012, 8:647-70. 10.2217\/fca.12.44","journal-title":"Future Cardiol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005008.pub4","article-title":"Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy","volume":"3","author":"van Dalen EC","year":"2016","unstructured":"van Dalen EC, van der Pal HJ, Kremer LC. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2016, 3:CD005008. 10.1002\/14651858.CD005008.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer\u00a0therapy: best practices in diagnosis, prevention, and management: pPart 1","volume":"70","author":"Chang HM","year":"2017","unstructured":"Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ET. Cardiovascular complications of cancer\u00a0therapy: best practices in diagnosis, prevention, and management: pPart 1. J Am Coll Cardiol. 2017, 70:2536-51. 10.1016\/j.jacc.2017.09.1096","journal-title":"J Am Coll Cardiol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.2174\/157016111201140327163302","article-title":"Cardiac side effects of chemotherapy: state of art and strategies for a correct management","volume":"12","author":"Perrino C","year":"2014","unstructured":"Perrino C, Schiattarella GG, Magliulo F, et al.. Cardiac side effects of chemotherapy: state of art and strategies for a correct management. Curr Vasc Pharmacol. 2014, 12:106-16. 10.2174\/157016111201140327163302","journal-title":"Curr Vasc Pharmacol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960210911","article-title":"Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography","volume":"21","author":"Cottin Y","year":"1998","unstructured":"Cottin Y, Touzery C, Dalloz F, et al.. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol. 1998, 21:665-70. 10.1002\/clc.4960210911","journal-title":"Clin Cardiol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"Martin E","year":"2009","unstructured":"Martin E, Thougaard AV, Grauslund M, et al.. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009, 255:72-9. 10.1016\/j.tox.2008.10.011","journal-title":"Toxicology"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1080\/088800100276370","article-title":"Cardiotoxicity in children after bone marrow transplantation","volume":"17","author":"Nicolini B","year":"2000","unstructured":"Nicolini B, Rovelli A, Uderzo C. Cardiotoxicity in children after bone marrow transplantation. Pediatr Hematol Oncol. 2000, 17:203-9. 10.1080\/088800100276370","journal-title":"Pediatr Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/76079-pediatric-chemotherapy-drugs-associated-with-cardiotoxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:51Z","timestamp":1707507051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/76079-pediatric-chemotherapy-drugs-associated-with-cardiotoxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.19658","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}